Clinical Performance and Safety Comparison of Stay Safe Link® With Stay Safe® in Patient on CAPD (CAPD-3) — CAPD-3

Continuous Ambulatory Peritoneal Dialysis Clinical Trial

Official title:
A Randomised, Open-label, Parallel Group, Multi-centre Controlled Study to Evaluate the Clinical Performance and Safety of Stay Safe Link® Compared With Stay Safe® in Patients With End-stage Kidney Disease on Continuous Ambulatory Peritoneal Dialysis

Status Completed

Clinical Trial Summary

This post-marketing study is undertaken to compare the clinical effectiveness and safety of two continuous ambulatory peritoneal dialysis produced by Fresenius Medical Care (FMC), i.e. Stay Safe® (STS) that is produced by a plant in Germany and Stay Safe Link® (SSL) that is produced in Malaysia. The study is an open labelled, randomised controlled trial where 434 patients in total will be randomised to either STS or SSL in a 1:1 ratio.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Continuous Ambulatory Peritoneal Dialysis

Clinical Trial Details

NCT number	NCT03177031
Study type	Interventional
Source	Penang Hospital, Malaysia
Contact
Status	Completed
Phase	N/A
Start date	June 13, 2017
Completion date	June 26, 2019

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00728806` - Biomarker for Peritoneal Ultrafiltration Failure	N/A
Recruiting	`NCT01041963` - The Effect of Enalapril and Losartan on Peritoneal Membrane in Continuous Ambulatory Peritoneal Dialysis Patients	Phase 4
Completed	`NCT00939952` - Ertapenem Pharmacokinetics in Patients in Continuous Ambulatory Peritoneal Dialysis	Phase 4
Withdrawn	`NCT01093547` - Open-label, Randomized Trial to Determine the Effect of Icodextrin Versus Dextrose (Dianeal 2.5%) in HOMA IR	Phase 4
Completed	`NCT01996930` - Steroid Impregnated Tape in the Treatment of Over-granulating Peritoneal Dialysis Exit Sites	Phase 3